ABCSG 64 / neoGRACE: An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+/HER2-negative early breast cancer
Condition studied
endocrine non-responsive ER+/HER2-negative early breast cancer
Investigational medicinal product(s)
Every trial of Epirubicin, Sacituzumab Govitecan, Docetaxel and Cyclophosphamide across our registers →
Eligibility
Primary endpoint
pCR at time of surgery
Endpoint detail
RCB at time of surgery, Long-term outcome i.e. event free survival (EFS), invasive disease-free survival (IDFS), invasive breast cancer-free survival (IBCFS), distance recurrence-free survival (DRFS) and overall survival (OS)
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-520759-10-00 on CTIS ↗ ← All trials in the EU